ALVERON PHARMA
Alveron produces drugs such as cyclodextrins, pro-coagualant cyclodextrins with a unique coagulation platform technology.
ALVERON PHARMA
Industry:
Biopharma Biotechnology Emergency Medicine Pharmaceutical
Founded:
2011-01-01
Address:
Nijmegen, Gelderland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.alveron.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
11.79 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS
Similar Organizations
METiS Therapeutics
METiS Therapeutics uses integrated drug discovery to develop medicines in a variety of illness areas.
Tierra Biosciences
Tierra Biosciences is a synthetic biology company that offers an AI-driven platform with a vast range of custom proteins for research.
Current Employees Featured
Founder
Investors List
Waterman Ventures
Waterman Ventures investment in Seed Round - Alveron Pharma
OostNL
OostNL investment in Seed Round - Alveron Pharma
Thuja Capital
Thuja Capital investment in Seed Round - Alveron Pharma
Netherlands Enterprise Agency
Netherlands Enterprise Agency investment in Debt Financing - Alveron Pharma
Official Site Inspections
http://www.alveron.com
- Host name: 147.62.236.23.bc.googleusercontent.com
- IP address: 23.236.62.147
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Alveron Pharma"
COMPANY | Alveron Pharma
Alveron Pharma was incorporated in March 2019 as a joint venture between Okklo Life Sciences, a company developing therapeutic cyclodextrins, and Sanquin, the Dutch Blood Supply Foundation, a world leader in coagulation …See details»
HOME | Alveron Pharma
Alveron’s drug OKL-1111 is positioned as a rapid, first line therapy as it has a truly universal mode of action, not requiring anticoagulant identification. OKL-1111 is being developed as a ready-to …See details»
NEWS - Alveron Pharma
Dec 6, 2024 About Alveron Pharma. ... Broadview Ventures is a mission-driven investment organization that makes targeted investments in early-stage companies to accelerate the development of innovative therapeutics, devices, …See details»
Alveron Pharma - Crunchbase Company Profile & Funding
Alveron Pharma develops treatment for hemorrhagic stroke, a severe unmet medical need. Alveron’s drug OKL-1111 strongly reduces hematoma expansion in a mouse model of …See details»
Alveron Pharma Announces Close of €5M Seed Extension …
Https://www.alveron.com. About Broadview Ventures. Broadview Ventures is a mission-driven investment organization that makes targeted investments in early-stage companies to …See details»
Alveron Pharma - Leadership Team - The Org
The Leadership Team at Alveron Pharma, comprising the CEO, Chief Technical Officer, Chief Operating Officer, and Chief Scientific Officer, strategizes and oversees the company’s …See details»
Alveron Pharma - Company Profile - Tracxn
Feb 14, 2025 Alveron Pharma. has raised a total funding of $11.8M over 3 rounds. Its first funding round was on May 16, 2019. What are the most recent funding rounds of Alveron …See details»
Alveron Pharma - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Alveron Pharma - VentureRadar
Alveron Pharma's proprietary cyclodextrin-based compounds accelerate, but not initiate, coagulation via a unique mechanism. These compounds can therefore be used as systemic …See details»
Alveron Pharma - Craft
Alveron Pharma is a biotech company developing a coagulation platform technology with a cyclodextrin-based anticoagulant reversal drug. Its proprietary cyclodextrin-based compounds …See details»
Alveron Pharma Overview | SignalHire Company Profile
Alveron Pharma is developing a unique coagulation platform technology with the world's first cyclodextrin-based anticoagulant reversal drug. Organization Website: alveron.com : Alveron …See details»
Alveron Pharma - Contacts, Employees, Board Members
Alveron produces drugs such as cyclodextrins, pro-coagualant cyclodextrins with a unique coagulation platform technology.See details»
Alveron Pharma - PitchBook
Alveron Pharma General Information Description. Developer of a coagulation technology designed to create a cyclodextrin-based anticoagulant reversal drug. The company's …See details»
Spin-Offs - Sanquin
Overview: Organization; Executive and supervisory board; Advisory and review councils; National Council of Users; Medical Advisory Council; Organizational chart; Sanquin's activities. ...See details»
Dutch-based Alveron Pharma raises €5M to advance therapy for ...
Dec 9, 2024 Nijmegen, The Netherlands-based Alveron Pharma, a clinical-stage company, announced on Monday that it has secured €5M in a Series Seed extension funding round led …See details»
Okklo’s hematology asset will be further developed by Alveron …
Alveron pharma closes series a round to advance a cyclodextrin based procoagulant medicine into the clinic Alveron Pharma, a newly incorporated company established by Okklo Life …See details»
Alveron Pharma Announces Close of €5M Seed Extension …
Nijmegen, The Netherlands, December 6, 2024 – Alveron Pharma is pleased to announce today the closing of a €5.0 million Series Seed extension financing to advance the development of its …See details»
Alveron Pharma closes series a round to advance a ... - Sanquin
May 16, 2019 This investment allows Alveron Pharma to select a lead compound, conduct non-clinical studies, and complete a first clinical study to demonstrate safety and obtain a first …See details»
Alveron Pharma Announces Close of €5M Seed Extension …
Dec 6, 2024 NIJMEGEN, Netherlands, December 06, 2024--Alveron Pharma closed a €5 million Series Seed extension financing (approx $5.28 m) to advance its innovative drug to treat …See details»
Alveron Pharma closes €5 million seed extension financing to …
Dec 10, 2024 Alveron Pharma has announced the closing of a €5 million series seed extension financing—worth approximately US$5.28 million—to advance the development of its …See details»